Covestor Ltd Boosts Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Covestor Ltd raised its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 114.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,325 shares of the biopharmaceutical company’s stock after buying an additional 2,312 shares during the quarter. Covestor Ltd’s holdings in Amicus Therapeutics were worth $41,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Wellington Management Group LLP boosted its stake in shares of Amicus Therapeutics by 18.8% during the fourth quarter. Wellington Management Group LLP now owns 28,461,994 shares of the biopharmaceutical company’s stock worth $268,112,000 after buying an additional 4,497,950 shares during the period. Norges Bank purchased a new stake in Amicus Therapeutics during the 4th quarter valued at approximately $29,033,000. Renaissance Technologies LLC lifted its position in Amicus Therapeutics by 174.1% during the 4th quarter. Renaissance Technologies LLC now owns 2,108,616 shares of the biopharmaceutical company’s stock worth $19,863,000 after acquiring an additional 1,339,316 shares during the period. Trexquant Investment LP grew its stake in shares of Amicus Therapeutics by 101.6% in the 4th quarter. Trexquant Investment LP now owns 966,049 shares of the biopharmaceutical company’s stock valued at $9,100,000 after purchasing an additional 486,827 shares during the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of Amicus Therapeutics by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 29,258,963 shares of the biopharmaceutical company’s stock valued at $275,619,000 after purchasing an additional 458,143 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on FOLD shares. StockNews.com lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, February 20th. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. Cantor Fitzgerald reissued an “overweight” rating and set a $21.00 price target on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Finally, Wells Fargo & Company reduced their price objective on shares of Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating for the company in a research report on Thursday, February 20th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $16.75.

Amicus Therapeutics Stock Up 2.7 %

FOLD stock opened at $6.90 on Wednesday. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01. The company’s 50-day moving average price is $8.59 and its 200 day moving average price is $9.59. Amicus Therapeutics, Inc. has a 52 week low of $6.20 and a 52 week high of $12.65. The company has a market cap of $2.12 billion, a P/E ratio of -38.33, a P/E/G ratio of 1.51 and a beta of 0.79.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.